Soy food intake and treatment outcomes of women undergoing assisted reproductive technology
Pretreatment intake of soy foods and soy isoflavones was positively related to the probability of live birth in a prospective cohort of women undergoing assisted reproduction.
Jose C. Vanegas, M.D., Myriam C. Afeiche, Ph.D., Audrey J. Gaskins, Sc.D., Lidia Mínguez-Alarcón, Ph.D., Paige L. Williams, Ph.D., Diane L. Wright, D.L., Ph.D., Thomas L. Toth, M.D., Russ Hauser, M.D., Sc.D., Jorge E. Chavarro, M.D., Sc.D.
Volume 103, Issue 3, Pages 749-755
To study the relation of dietary phytoestrogens intake and clinical outcomes of women undergoing infertility treatment with the use of assisted reproductive technology (ART).
Prospective cohort study.
A total of 315 women who collectively underwent 520 ART cycles from 2007 to 2013.
Main Outcome Measure(s):
Implantation, clinical pregnancy, and live birth rates per initiated cycle.
Soy isoflavones intake was positively related to live birth rates in ART. Compared with women who did not consume soy isoflavones, the multivariable-adjusted odds ratios of live birth (95% confidence interval) for women in increasing categories of soy isoflavones intake were 1.32 (0.76–2.27) for women consuming 0.54–2.63 mg/d, 1.87 (1.12–3.14) for women consuming 2.64–7.55 mg/d, and 1.77 (1.03–3.03) for women consuming 7.56–27.89 mg/d.
Dietary soy intake was positively related to the probability of having a live birth during infertility treatment with ART.